TScan Eyes Investor Rebound at TD Cowen with Key Cancer Data Ahead

WALTHAM, MA – February 25, 2026 – As TScan Therapeutics prepares to take the stage at the prestigious TD Cowen 46th Annual Health Care Conference next week, the company finds itself at a critical juncture. The Waltham-based biotechnology firm is poised to present its story to a discerning audience of investors and analysts, carrying both the weight of a battered stock price and the promise of a clinical pipeline brimming with potential catalysts.

The scheduled presentation on March 4th in Boston is more than a routine update; it's a high-stakes opportunity for TScan (Nasdaq: TCRX) to bridge a significant disconnect between its recent market performance and its scientific progress in the cutting-edge field of T cell receptor (TCR)-engineered T cell therapies. With key data readouts on the horizon, the investment community will be listening intently for signs that the company's ambitious vision is on a clear path to fruition.

The Weight of Expectation

Participation in a top-tier conference like TD Cowen's is a staple for clinical-stage biotechs, offering a vital platform for visibility and strategic communication. For TScan, however, this year's appearance carries heightened significance. The company's stock has endured a difficult year, shedding approximately 53% of its value even as the broader biotech sector has shown signs of recovery. Currently trading near the $1 mark, the valuation stands in stark contrast to the company's advancing clinical programs.

This presentation provides management a direct channel to address investor concerns and reframe the narrative around upcoming value-inflection points. Analysts and investors will be looking beyond the prepared slides, hoping to glean insights from the analyst-led Q&A session regarding clinical timelines, manufacturing scalability, and the company's cash runway. With a reported high cash burn rate, a common trait for research-intensive biotechs, questions about financial strategy and the path to potential commercialization will be paramount. The company's ability to articulate a confident and clear strategy could be crucial in rebuilding market sentiment.

A Pipeline Packed with Potential

At the heart of TScan's investment thesis is its deep pipeline of TCR-T therapies, particularly its lead program for hematologic malignancies. The company has been making steady, tangible progress with its ALLOHA™ trial, which aims to prevent relapse in cancer patients following allogeneic hematopoietic cell transplantation.

In December 2025, TScan presented encouraging updated data at the American Society of Hematology (ASH) Annual Meeting. The results showed that all three patients treated with its lead candidate, TSC-101, who had reached the two-year follow-up mark remained relapse-free, a notable outcome compared to the control arm. This data provided a strong foundation of clinical proof-of-concept.

The market is now anticipating the next major catalyst: data from Cohort C of the ALLOHA™ Phase 1 trial, expected in the second quarter of 2026. This cohort is especially important as it utilizes a new, commercial-ready manufacturing process, a critical step toward scalability and regulatory approval. Positive safety and early chimerism data from this group would significantly de-risk the program. Furthermore, TScan has guided that it plans to launch a pivotal trial for TSC-101 in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in the same quarter, a milestone that would move the therapy much closer to a potential commercial launch.

Bolstering its heme franchise, the company recently announced that the FDA had cleared Investigational New Drug (IND) applications for two new candidates, TSC-102-A01 and TSC-102-A03. These therapies target the same protein but for different patient populations defined by their HLA type, a set of genes crucial for immune recognition. This expansion is projected to nearly double the addressable U.S. patient population for TScan's heme program, with Phase 1 trials slated to begin in the second half of 2026. This strategic expansion demonstrates a forward-thinking approach to maximizing the reach of its therapeutic platform.

Navigating a Competitive TCR-T Landscape

TScan is not operating in a vacuum. The TCR-T therapy space is a hotbed of innovation and competition, populated by a mix of established players and agile startups, including Adaptimmune, Immatics, and Immunocore, the latter of which already has an FDA-approved TCR therapy on the market. These therapies are particularly prized for their potential to attack solid tumors by targeting intracellular proteins that are inaccessible to other cell therapies like CAR-T.

In this crowded field, differentiation is key. TScan's competitive edge lies in its proprietary discovery engine, the TargetScan platform. This technology allows the company to identify novel, highly specific T cell targets not just for cancer but also for T cell-mediated autoimmune disorders, opening up future avenues for growth beyond oncology.

The recent IND clearances for its TSC-102 candidates also highlight a core part of its strategy: systematically expanding the number of HLA types its therapies can address. This methodical approach aims to overcome a key limitation of many personalized cell therapies, gradually transforming a niche treatment into one applicable to a much broader patient base. Success in this area could set TScan apart from competitors focused on a narrower set of targets or patient populations.

The Analyst View and Market Disconnect

The starkest illustration of TScan's current situation is the chasm between its stock price and Wall Street's analysis. While the market has been punishing the stock, multiple analysts maintain "Buy" or "Strong Buy" ratings. Consensus 12-month price targets hover in a range of approximately $5.75 to $8.71, with some estimates reaching as high as $15.00. This suggests that experts who follow the company closely believe its underlying science and clinical progress are deeply undervalued.

Investors at the TD Cowen conference will be seeking the conviction to side with the analysts over the market's recent sentiment. They will want to hear management articulate a clear path to realizing this perceived value. This includes providing confidence in the upcoming ALLOHA™ trial data, clarifying the timeline for the pivotal study, and demonstrating prudent management of its financial resources.

The presentation serves as a critical test for TScan's leadership. It is their chance to remind the financial community that behind the lagging stock chart is a clinical-stage company advancing multiple programs, hitting key milestones, and preparing for late-stage development in an area of immense unmet medical need. How effectively they tell that story next week could set the tone for the company's valuation for months to come.